Physician profile
Marcy Goldstein
NPI 1942209028
$12,292.74
in general payments reported to CMS, 2019-2025
18 companies · $616 in 2025
The $616 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,464 · 2020: $6,355 · 2021: $758 · 2022: $698 · 2023: $822 · 2024: $581 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.88 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $9,184.00 | 2019-2021 | |
| Amgen INC. | $748.45 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $342.18 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $330.09 | 2021-2024 | Libtayo |
| Incyte Corporation | $223.96 | 2022-2023 | Opzelura |
| Pfizer INC. | $162.97 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $149.44 | 2025 | Zoryve |
| Abbvie INC. | $132.71 | 2022-2024 | |
| Janssen Biotech, INC. | $122.28 | 2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $120.29 | 2024 | Sotyktu |
| Kyowa Kirin, INC. | $118.74 | 2023 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.14 | 2025 | Cabtreo |
| Ucb, INC. | $108.76 | 2025 | Bimzelx |
| Leo Pharma INC. | $107.57 | 2023 | Adbry |
| Verrica Pharmaceuticals INC. | $106.32 | 2024 | Ycanth |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $105.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.67 | 2023 | Spevigo |
| Galderma Laboratories, L.P. | $16.54 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.